Tuberculosis compositions and methods of treating or preventing tuberculosis

A composition, technology of Mycobacterium tuberculosis, applied in the field of tuberculosis composition and treatment or prevention of tuberculosis

Pending Publication Date: 2019-06-14
INT AIDS VACCINE INITIATIVE INC
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although vaccines are often effective in immunizing individuals prophylactically or therapeutically against pathogenic infection or human disease, there remains a need for improved vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tuberculosis compositions and methods of treating or preventing tuberculosis
  • Tuberculosis compositions and methods of treating or preventing tuberculosis
  • Tuberculosis compositions and methods of treating or preventing tuberculosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0210] Embodiment 1. A composition or fusion protein comprising at least three Mycobacterium tuberculosis (Mtb) antigens, wherein the Mtb antigens are selected from the group consisting of Rv1009, Rv3136, Rv3615c, Rv2628, Rv2034 and Rv3136 N-terminus.

Embodiment approach 2

[0211] Embodiment 2. The composition or fusion protein of embodiment 1, wherein Rv1009 comprises the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:4.

Embodiment approach 3

[0212] Embodiment 3. The composition or fusion protein according to embodiment 1, wherein Rv1009 is encoded by the nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:3.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
volumeaaaaaaaaaa
Login to view more

Abstract

The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositionscomprising the same, and methods of eliciting an immune response against tuberculosis.

Description

technical field [0001] The present disclosure relates in part to fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the fusion proteins, vectors comprising the nucleic acid molecules, compositions comprising them and methods of eliciting an immune response against tuberculosis. Background technique [0002] Tuberculosis (TB) is a global health problem resulting in 8 million new cases and 2 million deaths each year. The emergence of multidrug-resistant and fully drug-resistant TB strains will only exacerbate the problem. The life cycle of Mtb has 3 phases. In the acute phase after initial infection, bacteria replicate and express virulence factors in the host, leading to an immune response in the host. As the immune response begins to control the infection, Mtb enters a latent, asymptomatic state in which the bacteria become non-replicating and become encapsulated in granulomas. The bacteria can exist in this latent state ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/04C07K14/35C07K19/00
CPCA61K2039/55561A61K2039/53A61P31/06A61K39/04C07K2319/00C07K14/35
Inventor 拉维·P·安纳萨托马斯·G·埃文斯奥雷利奥·M·博纳维亚
Owner INT AIDS VACCINE INITIATIVE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products